When was Signal Pharmaceuticals founded?

Signal Pharmaceuticals was founded in 1993 and raised its 1st funding round within a year of its incorporation.

Where is Signal Pharmaceuticals located?

Signal Pharmaceuticals is headquartered in San Diego, United States.

Is Signal Pharmaceuticals a funded company?

Signal Pharmaceuticals is a funded company, having raised a total of $12M across 2 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on 1993.

When was the latest funding round of Signal Pharmaceuticals?

Signal Pharmaceuticals' latest funding was a $***** Series E round on Sep 17, 1997, with participation from 4 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.25B in funding in 2026 to date.

Where does Signal Pharmaceuticals rank among its competitors?

Signal Pharmaceuticals ranks 46th amongst 242 active competitors, of which 76 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was eGenesis, which secured $14M in Aug, 2026.

Who are the top competitors of Signal Pharmaceuticals?

Signal Pharmaceuticals' top competitors include Beam Therapeutics, eGenesis and Mammoth. Among them, eGenesis secured the most recent funding round in August, 2026.

Signal Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Signal Pharmaceuticals is an acquired company based in San Diego (United States), founded in 1993 by David Anderson. It operates as a Discoverer of drugs to regulate disease-related genes. Signal Pharmaceuticals has raised $12M in funding. The company has 242 active competitors, including 76 funded and 21 that have exited. Its top competitors include companies like Beam Therapeutics, eGenesis and Mammoth.

Company Details

Signal Pharmaceuticals is engaged in the research and development of small molecule drugs that regulate disease-associated genes. It applies advanced cellular, molecular and genomic technologies so that it can map gene-regulating pathways in cells and to identify proprietary molecular targets that activate or deactivate genes and result in disease. Pharma companies will partner with Signal Pharma to discover drugs that regulate disease-associated genes involved.

Key Metrics

Founded Year

1993

Location

San Diego, United States

Stage

Acquired

Total Funding

$12M in 2 rounds

Latest Funding Round

Series E, Sep 17, 1997, $*****

Investors

Kleiner Perkins & 11 more

Ranked

46^th among 242 active competitors

Similar Companies

Beam Therapeutics & 261 more

Exit Details

Acquired by Celgene (Jun 30, 2000)

View Signal Pharmaceuticals' full profile

Signal Pharmaceuticals got acquired by Celgene on Jun 30, 2000 at an acquisition amount of $*****.

Click here to take a look at Signal Pharmaceuticals's acquisition in detail

Signal Pharmaceuticals has raised a total funding of $12M over 2 rounds. Its first funding round was on 1993. Its latest funding round was a Series E round on Sep 17, 1997 for $*****. 4 investors participated in its latest round. Signal Pharmaceuticals has 12 institutional investors.

Here is the list of recent funding rounds of Signal Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 1997	5697246	Series E	1731599	1317388	4774497	8014429
1993	7959	Series D	1826	2030	1160	Venrock

Access funding benchmarks and valuations. Sign up today!

View details of Signal Pharmaceuticals's funding rounds and investors

The founders of Signal Pharmaceuticals is David Anderson.

Here are the details of Signal Pharmaceuticals' key team members:

David Anderson: Former Co-Founder of Signal Pharmaceuticals.

View details of Signal Pharmaceuticals's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Signal Pharmaceuticals include Beam Therapeutics, eGenesis and Mammoth. Here is the list of Top 10 competitors of Signal Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
2nd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$495M	Monashee Investment Management, Farallon Capital Management ... & 31 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
4th	Scribe Therapeutics 2018, Alameda (United States), Public	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 7 others	65/100
5th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
6th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
7th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	T. Rowe Price, Redmile Group & 10 others	63/100
8th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, ADIA & 22 others	63/100
9th	Kytopen 2017, Cambridge (United States), Series B	Developer of gene delivery systems for cell therapy	$44.5M	Northpond Ventures, Horizons Ventures & 12 others	61/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	60/100
46th	Signal Pharmaceuticals 1993, San Diego (United States), Acquired	Discoverer of drugs to regulate disease-related genes	$12M	Kleiner Perkins, The Vertical Group & 10 others	40/100